Eosinophilic esophagitis (EoE) is a chronic, immune-mediated condition characterized by eosinophilic inflammation in the esophagus. It accounts for approximately 33.9 cases per 100,000 patient-years, with a prevalence of 147.4 per 100,000 individuals. The growing focus on targeted biologic therapies and novel drug formulations is driving the development of eosinophilic esophagitis drugs. According to the eosinophilic esophagitis pipeline analysis by Expert Market Research, the therapeutic landscape is expanding significantly with promising candidates in late-stage development.
Major companies involved in the eosinophilic esophagitis pipeline analysis include Celgene, Eupraxia Pharmaceuticals Inc., and others.
Leading drugs currently in the pipeline include CC-93538, EP-104IAR, and others.
Rising clinical trials, increased FDA designations, and biologics innovation (particularly monoclonal antibodies), are driving growth in the eosinophilic esophagitis drug pipeline, signaling strong therapeutic advancements and regulatory momentum.
The Eosinophilic Esophagitis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into eosinophilic esophagitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for eosinophilic esophagitis. The eosinophilic esophagitis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The eosinophilic esophagitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with eosinophilic esophagitis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to eosinophilic esophagitis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Eosinophilic esophagitis (EoE) is a chronic, immune-mediated inflammatory condition of the esophagus characterized by the accumulation of eosinophils, a type of white blood cell. It is often triggered by certain foods or allergens, leading to symptoms like painful swallowing, vomiting, and food impaction.
Eosinophilic esophagitis is typically managed through dietary modifications, proton pump inhibitors, and corticosteroids. Treatment aims to reduce inflammation, relieve symptoms, and prevent esophageal narrowing. In February 2024, Takeda received U.S. Food and Drug Administration approval for EOHILIA (budesonide oral suspension), the first and only oral treatment specifically formulated for eosinophilic esophagitis. The 12-week therapy demonstrated significant histologic remission and improvement in swallowing symptoms in clinical trials.
The incidence and prevalence of eosinophilic esophagitis (EoE) have shown a significant rise globally. According to Healio, the incidence is 33.9 per 100,000 person-years, while the prevalence is 147.4 per 100,000 individuals. Edoardo Vincenzo Savarino et al. (2024) reported regional differences, with higher rates in North America than in Europe. Navarro et al. found pooled prevalence at 34.4 per 100,000, with incidence rates of 7.7 in adults and 6.6 in children per 100,000 person-years. These findings highlight the growing need for targeted therapeutic development in eosinophilic esophagitis.
This section of the report covers the analysis of eosinophilic esophagitis drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total eosinophilic esophagitis clinical trials with 52%, highlighting strong mid-stage clinical development. Phase III and phase IV each account for 19%, indicating promising late-stage progress and post-marketing evaluations. Phase I holds 9.52%, reflecting active early-stage innovation. These advancements are expected to drive therapeutic breakthroughs and positively impact market growth and patient outcomes.
The drug molecule categories covered under the eosinophilic esophagitis pipeline analysis include small molecules, monoclonal antibodies, peptides, probiotics, and gene therapies. The eosinophilic esophagitis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for eosinophilic esophagitis. Immune-modulating peptides are emerging as a promising drug class in the treatment pipeline for eosinophilic esophagitis. For instance, ‘1104, a first-in-class immune-resetting peptide by Revolo Biotherapeutics, is undergoing clinical evaluation. It has shown potential in reducing eosinophilic inflammation and enhancing regulatory immune cell populations, offering a novel approach to managing this chronic allergic condition.
The EMR report for the eosinophilic esophagitis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed eosinophilic esophagitis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in eosinophilic esophagitis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for eosinophilic esophagitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of eosinophilic esophagitis drug candidates.
CC-93538, sponsored by Celgene, is a recombinant humanized monoclonal antibody targeting interleukin-13 (IL-13), a key cytokine in eosinophilic esophagitis (EoE) pathology. This Phase 3 open-label extension study is evaluating the long-term safety and tolerability of CC-93538 in adults and adolescents enrolled in earlier trials. By binding IL-13, the drug aims to reduce inflammation and prevent IL-13 receptor interaction, addressing chronic esophageal dysfunction in EoE.
EP-104IAR, sponsored by Eupraxia Pharmaceuticals Inc., is currently being evaluated in a Phase 1b/2a clinical trial for adults with eosinophilic esophagitis (EoE). The study is assessing the safety, pharmacokinetics, and local effects of this novel, injectable formulation of fluticasone propionate, a corticosteroid designed for extended release. The objective is to determine the recommended Phase 2 dose while examining its impact on inflammation and symptom relief in EoE patients.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Eosinophilic Esophagitis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for eosinophilic esophagitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into eosinophilic esophagitis collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share